Objective: In several cancers, the loss of skeletal muscle is well associated with oncological outcome. However, its effect is unknown in testicular cancer. This study evaluated the prognostic impact of psoas major muscle volume loss during systemic chemotherapy. Methods: This was a retrospective study of patients who underwent chemotherapy from 2008 to 2017. Psoas major muscle volume was calculated by volume analyzer software, and its loss was calculated during systemic chemotherapy. The patients were divided according to muscle volume loss: Group 1 (<20%) and Group 2 (≥20%). The losses were compared with Kaplan-Meier curves, and a Cox proportional hazard model was applied to test predictors of poor prognosis. Results: Fifty patients were included. Seventeen were classified into Group 1, and 33 into Group 2. The Kaplan-Meier curves revealed that the progression-free and the overall survival of Group 1 were significantly better than those of Group 2 (P = 0.002, P = 0.03, respectively). A multivariate analysis identified psoas major muscle volume loss as a significant and independent predictor of poor prognosis. Conclusions: Patients with psoas major muscle volume loss during chemotherapy had a significantly worse prognosis than those without loss.
Introduction
Testicular cancer (TC) is a relatively rare cancer, accounting for only 1-2% of all tumors in male patients (1) . TC is the most common malignancy in men between the ages of 20 and 40 years old (2) . In the United States, more than 9000 men are diagnosed with TC per year, and its incidence has been increasing over the past several decades (1) . Worldwide,~72 000 men have been diagnosed with TC, and 9000 have died from the disease (3).
Loss of muscle during anticancer treatment, including surgery and chemotherapy, is known to be a prognostic factor in several types of cancers: ovarian, lung, gastric, colorectal, pancreatic, hepatocellular, bladder and metastatic renal cancer (4) (5) (6) (7) (8) (9) (10) (11) . Some studies have also reported an association between sarcopenia and chemotherapy toxicity (12, 13) .
Recently, research has begun on the relationship between the loss of skeletal muscle (SM) and cancer prognosis or complications during chemotherapy, and studies involving several types of cancer have already been published. However, the association with TC is unclear, and the mechanism of this relationship is still not completely understood. The aim of this study was to evaluate whether the loss of SM during systemic chemotherapy was associated with TC progression and complications.
Materials and methods

Patients
We retrospectively identified 54 patients with TC who had undergone systemic chemotherapy from 2008 to 2017 at Okayama University Hospital, Japan. Those who could not undergo accurate psoas major muscle volume (PMV) measurement were excluded from this study.
CT protocol and body composition analysis
A computed tomography (CT) scan was performed using a 64-slice multidetector CT scanner (Toshiba Medical Systems Corporation, Tochigi, Japan). PMV was calculated automatically using volume analyzer software (Synapse Vincent ver. 4, Fujifilm, Tokyo, Japan). Figure 1a shows the PMV in axial, coronal and 3D images. This software automatically quantified PMV using threshold values of −29 to 150 Hounsfield units to distinguish muscle from other tissues. At the same time, the cross-sectional areas of SM were measured at the level of the third lumbar vertebra (L3) (Fig. 1b) . We routinely performed CT each course at the end of chemotherapy; Day 21. We investigated the rate of change for PMV and SM during first-line chemotherapy.
Statistical analysis
The patients were divided into two groups depending on the degree of PMV loss: Group 1 (<20%) and Group 2 (≥20%). Statistical comparisons of the patient characteristics were performed using the Fisher's exact test and Mann-Whitney U test, as appropriate. The Pearson correlation coefficient was used to measure the strength of the linear association between PMV and SM in pre-and postchemotherapy. The correlation between the PMV change and the SM change was evaluated using Bland-Altman plots. Kaplan-Meier curves were constructed, and the log-rank test was used to compare progression-free survival (PFS) and overall survival (OS) among groups. The relationship between clinical variables and progressive disease (PD) was examined using the Cox proportional hazard model. Receiver operating characteristic (ROC) curves were plotted to compare the different methods between PMV change and SM change for predicting PD. Statistical significance was set at P < 0.05 for all analyses. All the statistical analyses were performed using JMP 13.2 software (SAS Institute, Cary, NC, USA), and the EZR version 1.36 (Saitama Medical Center, Jichi Medical University), a graphical user interface for R (14) .
Results
Patient characteristics
Fifty patients were included in this retrospective study, and 17 patients were assigned to Group 2. The patient characteristics are shown in Table 1 . The median follow up time was 50.2 (2.4-111.2) months. We determined the course number for systemic chemotherapy according to the guideline (15) . With systemic chemotherapy, nearly all patients developed pancytopenia, and 30 patients were diagnosed with febrile neutropenia while receiving first-line chemotherapy. There was no significant difference between the groups.
Anthropometry characteristics and evaluation of muscle loss Table 2 shows PMV, SM and body weight (BW) before and after chemotherapy, and the percent changes. PMV decreased from 566 (269-1020) ml before to 476 (206-829) ml after chemotherapy, and the mean change was −15. Correlation between PMV and SM, and between their changes Figure 2a shows the correlation between PMV and SM. The Pearson correlation coefficient (r) between PMV and SM was 0.632 before chemotherapy. After chemotherapy, the Pearson correlation coefficient (r) was 0.728. The correlation between the PMV change and the SM change is shown in a Bland-Altman plot in Fig. 2b . Figure 3 shows PFS and OS in patients with TC treated with chemotherapy. The Kaplan-Meier curves and log-rank test results revealed that Group 2 had significantly worse PFS and OS compared with Group 1. The 5-year progression-free rates were 91% and 53%, and the 5-year survival rates were 97% and 76%, respectively.
Patient survival
ROC curve analyses of muscle components for predicting progressive disease except lung (Yes vs No, HR = 6.181, P = 0.004), and PMV change (<20% vs ≥20%, HR = 6.039, P = 0.008). A multivariate analysis identified the PMV loss after first-line chemotherapy as a significant and independent predictor of PD (HR = 4.681, P = 0.033) ( Table 3) .
Discussion
The present study showed that the loss of PMV was an independent risk factor for PD in patients with TC undergoing chemotherapy.
Furthermore, PMV change was a more precise predictive factor than SM change. These findings indicate that the loss of PMV could be a clinically meaningful and promising prognostic factor in TC. Several studies have reported the relationship between the loss of SM and oncological outcomes in various other types of cancer. A meta-analysis reported an association between low SM index (SMI) and worse survival in patients with solid tumors. This study included a total of 7843 patients from 38 studies, and showed that low SMI was associated with poor OS (HR = 1.44, 95% CI = 1.32-1.56, P < 0.001) (16) . A recent study showed that loss of SM during chemotherapy was associated with poor survival in patients with foregut cancer (HR = 2.66, 95% CI = 1.42-4.97, P = 0.002) (17) . Several urological cancer studies found that the loss of SM, or sarcopenia, was a relevant prognostic factor in metastatic renal cell carcinoma, bladder cancer, urothelial carcinoma of the upper urinary tract and prostate cancer, although there were no reports with regards to TC (10, 11, 18, 19) . To our knowledge, this is the first report to investigate the association between the loss of PMV and poor prognosis in TC. A recent study also showed that PMV is a better predictive factor than SM area for living donor liver transplantation (20) .
Although the loss of PMV has been associated with poor prognosis, the mechanism is not clear. Inflammatory cytokines are known to play a key role in the development of sarcopenia. The inflammatory cytokines interleukin-6 (IL-6) and TNF-α activate NF-κB through a receptor existing in muscle tissue, and the degradation of protein is progressive (21) . The downregulation of IL-15, also known as myokine, is also associated with sarcopenia (22) . These PMV, psoas major muscle volume. observations suggest that impaired immunity in sarcopenia may contribute to the poor progression observed in patients with TC. On the other hand, nausea and vomiting are frequently observed in patients receiving chemotherapy, and these symptoms could cause anorexia and decreased physical activity. In that case, the intake of protein would decrease and the catabolism of protein would increase. These factors could contribute to the loss of SM. SM in L3 is reasonably well correlated with whole body muscle mass, and SMI is widely used to evaluate sarcopenia and nutrition status (23) . The present study showed that SM was well correlated with PMV (Fig. 2) . Furthermore, PMV was a better predictive factor for prognosis than SM, according to the ROC curve. The advantages of this method are its greater ease, quickness and accuracy compared with previous area methods. The software provides highly reproducible results, and its use does not require special training. In a previous study, we validated the use of this software in renal volume (24) . Another advantage is that the measurement of PMV does not have additional costs, as all patients underwent whole-body CT for diagnosis and follow-up.
This study had some limitations. First, it was a retrospective study carried out at a single institution, and consisted of small numbers of patients and events. To investigate the prognostic role of PMV loss in TC, studies of multiple large cohorts are necessary. Second, the study had selection bias. The number of systemic chemotherapy courses differed across patients. Moreover, some patients developed interstitial pneumonia with bleomycin, and regimens were switched and continued as etoposide and cisplatin (EP). Third, we evaluated the correlation between muscle change and prognosis. The physical performance, muscle strength and nutritional status might correlate with the loss of SM. To elucidate the mechanism of the relationship between PMV loss and poor prognosis, these factors would be included. Furthermore, we compared the loss of PMV after first-line systemic chemotherapy. We analyzed longitudinal PMV change at 6, 9 and 12 months. At the 12-month time point, the median change rate was −5% in patients with no PMV loss, and −20% in patients with PMV loss. These patients would be affected by second-line chemotherapy or surgery, and therefore an investigation of these factors is necessary (data not shown, because of insufficient data). Finally, this was the first report with a cut-off value for the PMV change. The cut-off of SMI in L3 has been established: 43 cm 2 /m 2 with a BMI <25 kg/m 2 , and 53 cm 2 /m 2 with BMI ≥25 kg/m (25) . Some reports defined the cutoff of SMI change as −2% to −10% (7, 19, 26) . However, there have been no reports defining the cut-off of muscle volume change. We defined the cut-off of PMV change as −20% from ROC curve. Despite these limitations, the study demonstrated that the loss of PMV calculated by CT was a novel method to evaluate the prognostic risk for patients undergoing first-line chemotherapy, using simple, quick and automatic methods. This new tool for calculating the loss of PMV has the potential to detect patients with a poor prognosis in TC. In conclusion, the loss of PMV calculated from CT was an independent risk factor for poor prognosis in patients with TC undergoing systemic chemotherapy. 
